Overactive Bladder (OAB) Therapeutics Market Report

Global and Region Overactive Bladder (OAB) Therapeutics Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Aug 02, 2022
  • PAGES：227
  • REPORT CODE：GMM988680
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Overactive Bladder (OAB) Therapeutics market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Overactive Bladder (OAB) Therapeuticsmarket, defines the market attractiveness level of Overactive Bladder (OAB) Therapeutics market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Overactive Bladder (OAB) Therapeutics industry, describes the types of Overactive Bladder (OAB) Therapeutics market, the applications of major players and the market size, and deeply analyzes the current situation of the global Overactive Bladder (OAB) Therapeutics market and the development prospects and opportunities of Overactive Bladder (OAB) Therapeutics industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Overactive Bladder (OAB) Therapeutics market in Chapter 13.

    By Player:

    • GSK

    • Kwang Dong Pharmaceutical 

    • Pfizer 

    • Allergan 

    • Ion Channel Innovations 

    • Merck 

    • ONO Pharmaceutical 

    • Hisamitsu Pharmaceutical 

    • Teva Pharmaceutical Industries 

    • Urovant Sciences

    • Astellas Pharma 

    • Ferring 

    By Type:

    • Anticholinergic Agents

    • Beta-3 Adrenoreceptor Agonists

    By End-User:

    • Hosptial

    • Clinci

    • Other

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Overactive Bladder (OAB) Therapeutics Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Overactive Bladder (OAB) Therapeutics Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Overactive Bladder (OAB) Therapeutics Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Overactive Bladder (OAB) Therapeutics Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Overactive Bladder (OAB) Therapeutics Market Analysis and Outlook to 2022

    • 7.1 Global Overactive Bladder (OAB) Therapeutics Consumption (2017-2022)

    • 7.2 United States Overactive Bladder (OAB) Therapeutics Consumption (2017-2022)

    • 7.3 Europe Overactive Bladder (OAB) Therapeutics Consumption (2017-2022)

    • 7.4 China Overactive Bladder (OAB) Therapeutics Consumption (2017-2022)

    • 7.5 Japan Overactive Bladder (OAB) Therapeutics Consumption (2017-2022)

    • 7.6 India Overactive Bladder (OAB) Therapeutics Consumption (2017-2022)

    • 7.7 South Korea Overactive Bladder (OAB) Therapeutics Consumption (2017-2022)

    8 Region and Country-wise Overactive Bladder (OAB) Therapeutics Market Analysis and Outlook to 2028

    • 8.1 Global Overactive Bladder (OAB) Therapeutics Consumption Forecast (2022-2028)

    • 8.2 United States Overactive Bladder (OAB) Therapeutics Consumption Forecast (2022-2028)

    • 8.3 Europe Overactive Bladder (OAB) Therapeutics Consumption Forecast (2022-2028)

    • 8.4 China Overactive Bladder (OAB) Therapeutics Consumption Forecast (2022-2028)

    • 8.5 Japan Overactive Bladder (OAB) Therapeutics Consumption Forecast (2022-2028)

    • 8.6 India Overactive Bladder (OAB) Therapeutics Consumption Forecast (2022-2028)

    • 8.7 South Korea Overactive Bladder (OAB) Therapeutics Consumption Forecast (2022-2028)

    9 Global Overactive Bladder (OAB) Therapeutics Market Outlook by Types and Applications to 2022

    • 9.1 Global Overactive Bladder (OAB) Therapeutics Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Anticholinergic Agents Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Beta-3 Adrenoreceptor Agonists Consumption and Growth Rate (2017-2022)

    • 9.2 Global Overactive Bladder (OAB) Therapeutics Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hosptial Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Clinci Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Other Consumption and Growth Rate (2017-2022)

    10 Global Overactive Bladder (OAB) Therapeutics Market Outlook by Types and Applications to 2028

    • 10.1 Global Overactive Bladder (OAB) Therapeutics Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Anticholinergic Agents Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Beta-3 Adrenoreceptor Agonists Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Overactive Bladder (OAB) Therapeutics Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Hosptial Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Clinci Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Other Consumption Forecast and Growth Rate (2022-2028)

    11 Global Overactive Bladder (OAB) Therapeutics Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Overactive Bladder (OAB) Therapeutics Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Overactive Bladder (OAB) Therapeutics Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Overactive Bladder (OAB) Therapeutics Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Overactive Bladder (OAB) Therapeutics Market Competitive Analysis

    • 14.1 GSK

      • 14.1.1 GSK Company Details

      • 14.1.2 GSK Overactive Bladder (OAB) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 GSK Overactive Bladder (OAB) Therapeutics Product and Service

    • 14.2 Kwang Dong Pharmaceutical 

      • 14.2.1 Kwang Dong Pharmaceutical  Company Details

      • 14.2.2 Kwang Dong Pharmaceutical  Overactive Bladder (OAB) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Kwang Dong Pharmaceutical  Overactive Bladder (OAB) Therapeutics Product and Service

    • 14.3 Pfizer 

      • 14.3.1 Pfizer  Company Details

      • 14.3.2 Pfizer  Overactive Bladder (OAB) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Pfizer  Overactive Bladder (OAB) Therapeutics Product and Service

    • 14.4 Allergan 

      • 14.4.1 Allergan  Company Details

      • 14.4.2 Allergan  Overactive Bladder (OAB) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Allergan  Overactive Bladder (OAB) Therapeutics Product and Service

    • 14.5 Ion Channel Innovations 

      • 14.5.1 Ion Channel Innovations  Company Details

      • 14.5.2 Ion Channel Innovations  Overactive Bladder (OAB) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Ion Channel Innovations  Overactive Bladder (OAB) Therapeutics Product and Service

    • 14.6 Merck 

      • 14.6.1 Merck  Company Details

      • 14.6.2 Merck  Overactive Bladder (OAB) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Merck  Overactive Bladder (OAB) Therapeutics Product and Service

    • 14.7 ONO Pharmaceutical 

      • 14.7.1 ONO Pharmaceutical  Company Details

      • 14.7.2 ONO Pharmaceutical  Overactive Bladder (OAB) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 ONO Pharmaceutical  Overactive Bladder (OAB) Therapeutics Product and Service

    • 14.8 Hisamitsu Pharmaceutical 

      • 14.8.1 Hisamitsu Pharmaceutical  Company Details

      • 14.8.2 Hisamitsu Pharmaceutical  Overactive Bladder (OAB) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Hisamitsu Pharmaceutical  Overactive Bladder (OAB) Therapeutics Product and Service

    • 14.9 Teva Pharmaceutical Industries 

      • 14.9.1 Teva Pharmaceutical Industries  Company Details

      • 14.9.2 Teva Pharmaceutical Industries  Overactive Bladder (OAB) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Teva Pharmaceutical Industries  Overactive Bladder (OAB) Therapeutics Product and Service

    • 14.10 Urovant Sciences

      • 14.10.1 Urovant Sciences Company Details

      • 14.10.2 Urovant Sciences Overactive Bladder (OAB) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Urovant Sciences Overactive Bladder (OAB) Therapeutics Product and Service

    • 14.11 Astellas Pharma 

      • 14.11.1 Astellas Pharma  Company Details

      • 14.11.2 Astellas Pharma  Overactive Bladder (OAB) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 Astellas Pharma  Overactive Bladder (OAB) Therapeutics Product and Service

    • 14.12 Ferring 

      • 14.12.1 Ferring  Company Details

      • 14.12.2 Ferring  Overactive Bladder (OAB) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.12.3 Ferring  Overactive Bladder (OAB) Therapeutics Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Overactive Bladder (OAB) Therapeutics

    • Figure Overactive Bladder (OAB) Therapeutics Picture

    • Table Global Overactive Bladder (OAB) Therapeutics Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Overactive Bladder (OAB) Therapeutics Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Overactive Bladder (OAB) Therapeutics Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Overactive Bladder (OAB) Therapeutics Consumption by Country (2017-2022)

    • Figure United States Overactive Bladder (OAB) Therapeutics Consumption and Growth Rate (2017-2022)

    • Table Europe Overactive Bladder (OAB) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure China Overactive Bladder (OAB) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Japan Overactive Bladder (OAB) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure India Overactive Bladder (OAB) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure South Korea Overactive Bladder (OAB) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Global Overactive Bladder (OAB) Therapeutics Consumption Forecast by Country (2022-2028)

    • Figure United States Overactive Bladder (OAB) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Overactive Bladder (OAB) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Overactive Bladder (OAB) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Overactive Bladder (OAB) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Overactive Bladder (OAB) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Overactive Bladder (OAB) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Anticholinergic Agents Consumption and Growth Rate (2017-2022)

    • Figure Global Beta-3 Adrenoreceptor Agonists Consumption and Growth Rate (2017-2022)

    • Figure Global Hosptial Consumption and Growth Rate (2017-2022)

    • Figure Global Clinci Consumption and Growth Rate (2017-2022)

    • Figure Global Other Consumption and Growth Rate (2017-2022)

    • Figure Global Anticholinergic Agents Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Beta-3 Adrenoreceptor Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hosptial Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinci Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Other Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Overactive Bladder (OAB) Therapeutics Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Overactive Bladder (OAB) Therapeutics Export by Region (Top 5 Countries) (2017-2028)

    • Table GSK (Foundation Year, Company Profile and etc.)

    • Table GSK Overactive Bladder (OAB) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table GSK Overactive Bladder (OAB) Therapeutics Product and Service

    • Table Kwang Dong Pharmaceutical  (Foundation Year, Company Profile and etc.)

    • Table Kwang Dong Pharmaceutical  Overactive Bladder (OAB) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Kwang Dong Pharmaceutical  Overactive Bladder (OAB) Therapeutics Product and Service

    • Table Pfizer  (Foundation Year, Company Profile and etc.)

    • Table Pfizer  Overactive Bladder (OAB) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer  Overactive Bladder (OAB) Therapeutics Product and Service

    • Table Allergan  (Foundation Year, Company Profile and etc.)

    • Table Allergan  Overactive Bladder (OAB) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Allergan  Overactive Bladder (OAB) Therapeutics Product and Service

    • Table Ion Channel Innovations  (Foundation Year, Company Profile and etc.)

    • Table Ion Channel Innovations  Overactive Bladder (OAB) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Ion Channel Innovations  Overactive Bladder (OAB) Therapeutics Product and Service

    • Table Merck  (Foundation Year, Company Profile and etc.)

    • Table Merck  Overactive Bladder (OAB) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Merck  Overactive Bladder (OAB) Therapeutics Product and Service

    • Table ONO Pharmaceutical  (Foundation Year, Company Profile and etc.)

    • Table ONO Pharmaceutical  Overactive Bladder (OAB) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table ONO Pharmaceutical  Overactive Bladder (OAB) Therapeutics Product and Service

    • Table Hisamitsu Pharmaceutical  (Foundation Year, Company Profile and etc.)

    • Table Hisamitsu Pharmaceutical  Overactive Bladder (OAB) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Hisamitsu Pharmaceutical  Overactive Bladder (OAB) Therapeutics Product and Service

    • Table Teva Pharmaceutical Industries  (Foundation Year, Company Profile and etc.)

    • Table Teva Pharmaceutical Industries  Overactive Bladder (OAB) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Teva Pharmaceutical Industries  Overactive Bladder (OAB) Therapeutics Product and Service

    • Table Urovant Sciences (Foundation Year, Company Profile and etc.)

    • Table Urovant Sciences Overactive Bladder (OAB) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Urovant Sciences Overactive Bladder (OAB) Therapeutics Product and Service

    • Table Astellas Pharma  (Foundation Year, Company Profile and etc.)

    • Table Astellas Pharma  Overactive Bladder (OAB) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Astellas Pharma  Overactive Bladder (OAB) Therapeutics Product and Service

    • Table Ferring  (Foundation Year, Company Profile and etc.)

    • Table Ferring  Overactive Bladder (OAB) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Ferring  Overactive Bladder (OAB) Therapeutics Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US